Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Factors tied to outcomes following ranibizumab, PRP treatment for diabetic retinopathy

05 Aug 2018

In the treatment of proliferative diabetic retinopathy (DR), eyes gain vision and rarely develop vision-impairing central-involved diabetic macula oedema (DME) over 2 years with ranibizumab, according to a posthoc analysis. In contrast, factors such as poor glycaemic control and more severe DR increase the likelihood of losing visual acuity and developing DME following panretinal photocoagulation (PRP).

The present analysis involved two cohorts from the Diabetic Retinopathy Clinical Research Network Protocol S, one with available 2-year follow-up data (328 eyes) and another without vision-impairing central-involved DME at baseline (302 eyes). Study eyes had proliferative DR, no prior PRP and best-corrected visual acuity letter score of at least 24 (Snellen equivalent, 20/320 or better). Treatment with either intravitreous ranibizumab (0.5 mg/0.05 ml) or PRP was given.

In the ranibizumab group, no factors emerged as associated with the main outcome measures of change in visual acuity and development of vision-impairing (20/32 or worse) central-involved DME over 2 years.

In the PRP group, on the other hand, worse change in visual acuity was more likely to occur with higher glycated haemoglobin level (HbA1c; –0.6 letters per 1 percent increase; p=0.03), more severe DR (high-risk DR or worse vs moderate DR or better: difference, –2.8 letters; p=0.003) and higher mean arterial pressure (≥100 mm Hg vs <100 mm Hg: difference, –2.0 letters; p=0.009).

Likewise, eyes treated with PRP were at high risk of developing vision-impairing central-involved DME in the presence of higher HbA1c level (hazard ratio [HR] per 1 percent increase, 1.31; p<0.001), more severe DR (high-risk DR or worse vs moderate DR or better: HR, 1.46; p=0.03) and cystoid abnormalities within 500 μm of the macula centre (HR, 2.90; p=0.006).

The present data provide information on factors that potentially influence the outcomes associated with each treatment method for proliferative DR, although they hardly inform decision-making when it comes to selecting one treatment over the other, researchers said.

Given that PRP or anti-VEGF as monotherapies can be effective treatments for DR, it is likely that clinicians will continue to consider both in the management of patients, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.